Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Richard Shippy, Lisa Shaffer, Michel Bouchard

Premium

Richard Shippy has joined Illumina as director of global product marketing for clinical genomics within the San Diego vendor's diagnostics division.

In his new role, Shippy will be responsible for product marketing activities covering clinical genomics with an emphasis on cytogenomics, and will be working with BlueGnome to advance array designs for that market segment. Illumina acquired BlueGnome in September.

Shippy previously worked at Affymetrix for five years, where he held various positions, most recently senior director of strategic product marketing for clinical applications. Prior to joining Affy, Shippy was a senior scientist and computational biologist for GE Healthcare's CodeLink bioarray business.


Lisa Shaffer has left PerkinElmer to found Paw Print Genetics. According to the firm's website, Spokane, Wash.-based Paw Print Genetics is a clinical laboratory focused on genetic diagnostic testing for affected dogs and carrier screening for more than 100 inherited disorders prior to breeding.

Shaffer was previously chief scientific officer for molecular diagnostics at PerkinElmer and president of its Signature Genomics business. She co-founded Signature with Bassem Bejjani in 2003 and sold the company to PerkinElmer in 2010. Bejjani left PerkinElmer last year.


Illumina's board appointed Michel Bouchard as its chief accounting officer, effective Jan. 1. He will continue to serve as vice president of finance for the firm, as well, a title he has held since joining Illumina in 2008.

Before landing at Illumina, Bouchard held senior finance and accounting positions at Websense, and was VP of finance and accounting from 2007 to 2008.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.